Cancer Research Cancer Research Funding Available  Genetics and Biology of Brain Cancer
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Lehman, T. A.
Right arrow Articles by Turner, B. C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lehman, T. A.
Right arrow Articles by Turner, B. C.
[Cancer Research 60, 1062-1069, February 15, 2000]
© 2000 American Association for Cancer Research


Molecular Biology and Genetics

Elevated Frequency and Functional Activity of a Specific Germ-Line p53 Intron Mutation in Familial Breast Cancer1

Teresa A. Lehman, Bruce G. Haffty, Christopher J. Carbone, Lisa R. Bishop, Andrew A. Gumbs, Shiva Krishnan, Peter G. Shields, Rama Modali and Bruce C. Turner2

BioServe Biotechnologies [T. A. L., L. R. B., R. M.], Laurel, Maryland 20707; Departments of Therapeutic Radiology [B. G. H.] and Surgery [A. A. G.], Yale University School of Medicine, New Haven, Connecticut 06520; Laboratory of Human Carcinogenesis, National Cancer Institute, NIH, Bethesda, Maryland 20892 [S. K., P. G. S.]; and Department of Radiation Oncology and Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, Pennsylvania 19107-5097 [C. J. C., B. C. T.]

Previous studies have determined that the frequency of germ-line p53 mutations in familial breast cancer patients is 1% or less, but these reports have not investigated the importance of polymorphic intron base changes in the p53 gene. Therefore, we investigated the frequency of both exon and intron germ-line p53 base changes in 42 breast cancer patients with a strong family history of breast cancer. The mean age of presentation of these patients was 44.0 years (range, 29–69), and 12 of 42 (29%) were of known Ashkenazi ancestry. Purified DNA obtained from the 42 index cases was screened for germ-line p53 mutations in exons 2–11 and surrounding introns using a combination of intron based primers for PCR-single strand conformation polymorphism analysis, direct sequencing, and microarray sequencing using the Affymetrix p53 gene chip methodology. Morphological analysis of apoptosis and cell survival determination were performed on EBV-immortalized lymphoblastoid cell lines from two patients with the p53 intron 6 mutation. A germ-line mutation in the p53 gene at nucleotide 13964 with a G to C base change (13964GC) was identified in 3 of 42 (7.1%) hereditary breast cancer patients. Two patients were heterozygous for this mutation, and one patient had a homozygous mutation. In comparison, 0 of 171 (0%) of sporadic breast cancer patients had the p53 13964GC mutation (P = 0.0003). We found that 0 of 42 (0%) of these hereditary breast cancer patients had other germ-line p53 mutation in exons 2–11. However, pedigree analysis demonstrated that all three patients had strong family histories of multiple types of cancers consistent with Li-Fraumeni syndrome but with late age of onset. Comprehensive BRCA1 and BRCA2 nucleotide analysis from patients with the p53 13964GC mutation revealed no concomitant deleterious BRCA1 or BRCA2 mutations, although they were found in the other hereditary breast cancer patients. Functional analysis of two immortalized lymphoblastoid cell lines derived from patients with the p53 13964GC mutation demonstrated prolonged in vitro survival in response to cisplatinum treatment and showed decreased chemotherapy-induced apoptosis. Immunohistochemical analysis of breast tumors from these patients revealed high levels of mutant p53 protein, suggesting a functional mutation in the p53 gene. In summary, we have identified a single p53 intron mutation in familial breast cancer patients that is present at elevated frequency and has functional activity.




This article has been cited by other articles:


Home page
Cancer Epidemiol. Biomarkers Prev.Home page
P. Sun, Y. Qiu, Z. Zhang, J. Wan, T. Wang, X. Jin, Q. Lan, N. Rothman, and Z.-l. Xia
Association of Genetic Polymorphisms, mRNA Expression of p53 and p21 with Chronic Benzene Poisoning in a Chinese Occupational Population
Cancer Epidemiol. Biomarkers Prev., June 1, 2009; 18(6): 1821 - 1828.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
K. Chen, Z. Hu, L.-E Wang, W. Zhang, A. K. El-Naggar, E. M. Sturgis, and Q. Wei
Polymorphic TP53BP1 and TP53 Gene Interactions Associated with Risk of Squamous Cell Carcinoma of the Head and Neck
Clin. Cancer Res., July 15, 2007; 13(14): 4300 - 4305.
[Abstract] [Full Text] [PDF]


Home page
Cancer Epidemiol. Biomarkers Prev.Home page
T. E. Rohan, S.-Q. Li, R. Hartwick, and R. A. Kandel
p53 Alterations and Protein Accumulation in Benign Breast Tissue and Breast Cancer Risk: A Cohort Study.
Cancer Epidemiol. Biomarkers Prev., July 1, 2006; 15(7): 1316 - 1323.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Pathol.Home page
S Mitra, C Misra, R K Singh, C K Panda, and S Roychoudhury
Association of specific genotype and haplotype of p53 gene with cervical cancer in India
J. Clin. Pathol., January 1, 2005; 58(1): 26 - 31.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
J. Listgarten, S. Damaraju, B. Poulin, L. Cook, J. Dufour, A. Driga, J. Mackey, D. Wishart, R. Greiner, and B. Zanke
Predictive Models for Breast Cancer Susceptibility from Multiple Single Nucleotide Polymorphisms
Clin. Cancer Res., April 15, 2004; 10(8): 2725 - 2737.
[Abstract] [Full Text] [PDF]


Home page
J. Med. Genet.Home page
A-M Martin, P A Kanetsky, B Amirimani, T A Colligon, G Athanasiadis, H A Shih, M R Gerrero, K Calzone, T R Rebbeck, and B L Weber
Germline TP53 mutations in breast cancer families with multiple primary cancers: is TP53 a modifier of BRCA1?
J. Med. Genet., April 1, 2003; 40(4): e34 - 34.
[Full Text] [PDF]


Home page
Ann OncolHome page
K. Leroy, C. Haioun, E. Lepage, N. Le Metayer, F. Berger, E. Labouyrie, V. Meignin, B. Petit, C. Bastard, G. Salles, et al.
p53 gene mutations are associated with poor survival in low and low-intermediate risk diffuse large B-cell lymphomas
Ann. Onc., July 1, 2002; 13(7): 1108 - 1115.
[Abstract] [Full Text] [PDF]


Home page
Mol. Cell. Biol.Home page
T. K. MacLachlan, R. Takimoto, and W. S. El-Deiry
BRCA1 Directs a Selective p53-Dependent Transcriptional Response towards Growth Arrest and DNA Repair Targets
Mol. Cell. Biol., June 15, 2002; 22(12): 4280 - 4292.
[Abstract] [Full Text] [PDF]


Home page
JNCI J Natl Cancer InstHome page
X. Wu, H. Zhao, C. I. Amos, S. Shete, N. Makan, W. K. Hong, F. F. Kadlubar, and M. R. Spitz
p53 Genotypes and Haplotypes Associated With Lung Cancer Susceptibility and Ethnicity
J Natl Cancer Inst, May 1, 2002; 94(9): 681 - 690.
[Abstract] [Full Text] [PDF]


Home page
J. Nutr.Home page
K. D. Hirschi, J. A. Kreps, and K. K. Hirschi
Molecular Approaches to Studying Nutrient Metabolism and Function: An Array of Possibilities
J. Nutr., May 1, 2001; 131(5): 1605S - 1609.
[Abstract] [Full Text]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2000 by the American Association for Cancer Research.